Business context and reporting period
The supplied filing is Galena Biopharma, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2013—not a filing identified as SELLAS Life Sciences Group, Inc. Investors should verify the company and filing identity. Galena was developing oncology immunotherapies, including Phase 3 NeuVax, and had acquired U.S. rights to Abstral, its first commercial product. The company reported its first Abstral revenue in Q3; its official U.S. launch began in October 2013.
Financial results and position
| Metric | Q3 or September 30, 2013 | Comparable period / change |
|---|---|---|
| Revenue | $1.17 million | None in Q3 2012 |
| Gross profit and margin | $0.87 million; 74% | No prior-period revenue |
| Operating expenses | $7.76 million | $5.53 million in Q3 2012 |
| Operating loss | $6.89 million | $5.53 million in Q3 2012 |
| Net loss | $9.29 million; $0.11 per share | $6.26 million; $0.09 per share in Q3 2012 |
| Cash used in operations | $20.44 million for nine months | $15.80 million for nine months ended September 30, 2012 |
| Cash and cash equivalents | $51.40 million | $32.81 million at December 31, 2012 |
| Assets / liabilities | $91.25 million / $56.63 million | $54.99 million / $27.23 million at December 31, 2012 |
| Long-term debt carrying value | $9.80 million, including $1.22 million current | No long-term debt at December 31, 2012 |
Cash, marketable securities and net accounts receivable totaled approximately $55.8 million. Current assets were $56.8 million and current liabilities $36.5 million. The company also reported $24.3 million of potentially cash-settleable warrant liabilities and $6.7 million of contingent purchase-price consideration. These fair-value liabilities are distinct from borrowings. Nine-month financing cash inflows of $48.3 million, principally equity proceeds and debt, more than offset operating and investing cash outflows.
Material changes versus prior periods
- Q3 net loss rose approximately 48% year over year, as commercial launch preparation and higher selling, general and administrative costs outweighed initial revenue.
- Q3 R&D expense declined 13% year over year, but nine-month R&D expense increased 33% to $14.0 million, mainly due to the Phase 3 PRESENT trial ramp-up.
- Q3 SG&A increased 204% to $4.13 million, primarily from Abstral commercial staffing, marketing and related services.
- Nine-month net loss improved to $28.2 million from $31.2 million in 2012, partly because of lower non-operating warrant remeasurement expense and gains on RXi share sales. These items are not equivalent to recurring operating improvement.
- The September public offering generated $37.5 million in net proceeds; common shares issued increased from 83.6 million at year-end to 105.6 million at September 30.
Outlook, commentary and risks
Management expected continued operating losses while commercializing Abstral and advancing clinical programs. It said existing working capital should fund operations for the foreseeable future, but gave no quantified runway or revenue/profit forecast. A further $5 million debt tranche was available only if specified conditions were met. Management cautioned that funding might not be available on acceptable terms and that the company might need to curtail operations if revenues or financing proved inadequate.
- Abstral commercialization was early-stage and dependent on market acceptance, payer coverage, sales execution, compliant manufacturing and regulatory compliance. Orexo’s agreement required a specified minimum sales force through 2015; breach could allow Orexo to reacquire the U.S. rights. The company paid a $5 million milestone on October 3, 2013, after quarter-end.
- Abstral sales were concentrated: two customers accounted for 63% and 19% of Q3 sales, and one customer represented 81% of quarter-end receivables.
- NeuVax remained investigational. The filing cited clinical-trial enrollment, safety, efficacy, regulatory approval and possible additional-trial requirements as risks; the FDA Special Protocol Assessment did not assure approval.
- Warrant-liability remeasurement materially affected reported non-operating results and is sensitive to valuation assumptions. RXi marketable securities were exposed to share-price risk.
- The company reported no material impairment of goodwill or indefinite-lived intangibles. It maintained a full valuation allowance against net deferred tax assets. Disclosure controls were judged effective, with no material change in internal control reported.
Important facts for investors to verify
- Confirm the issuer: the provided filing names Galena Biopharma, Inc., while the request identifies SELLAS Life Sciences Group, Inc.
- Review subsequent Abstral launch performance, sales deductions and returns, customer concentration, payer access, and the continuing commercial-force commitment.
- Assess cash burn and financing needs against management’s unquantified “foreseeable future” liquidity statement, including eligibility for the remaining debt tranche.
- Track PRESENT and other clinical-trial enrollment, milestones, safety findings and regulatory developments.
- Examine dilution and potential cash obligations from the public-offering warrants, other warrants, debt terms and contingent purchase consideration.